Bronchial Hyperreactivity in the COVID-19 Era: The Impact of SARS-CoV-2 Infection and COVID-19 Vaccination in Patients with Respiratory Symptoms
Authors:
- Mei-Chen YangMYMei-Chen Yang
- Chung LeeCLChung Lee
- Lun-Yu JaoLJLun-Yu Jao
- Chun-Yao HuangCHChun-Yao Huang
- Yao-Kuang WuYWYao-Kuang Wu
- Kuo-Liang HuangKHKuo-Liang Huang
- Wen-Lin SuWSWen-Lin Su
- I-Shiang TzengI-Shiang Tzeng
- Chou-Chin LanCLChou-Chin Lan
Open Access
- 1 April 2026
- journal article
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 19, 1-12
Abstract
Persistent respiratory symptoms are commonly reported following coronavirus disease 2019 (COVID-19). Although COVID-19 vaccines are effective, concerns remain regarding their potential impact on airway hypersensitivity. The relationship between SARS-CoV-2 infection, vaccination, and bronchial hyperresponsiveness remains unclear. This retrospective study included adults aged ≥18 years who underwent methacholine provocation testing. Participants were categorized into four groups according to their history of SARS-CoV-2 infection and COVID-19 vaccination: no infection/no vaccination (NI-NV), vaccination/no infection (V-NI), no vaccination/infection (NV–I), and vaccination/infection (V–I). Airway hypersensitivity was defined as a ≥20% reduction in forced expiratory volume in one second (FEV1) following methacholine challenge. Multivariable logistic regression analysis was performed to evaluate independent associations. A total of 340 participants were included (NI-NV: n=36; V-NI: n=163; NV-I: n=25; V-I: n=116). No significant differences were observed in methacholine positivity, pulmonary function parameters, or PC20 values across groups (all p>0.05). In multivariable analysis, neither prior infection (adjusted OR 0.99, 95% CI 0.63–1.55) nor vaccination (adjusted OR 1.06, 95% CI 0.60–1.88) was independently associated with bronchial hyperresponsiveness. Smoking was significantly associated with methacholine positivity (adjusted OR 3.33, 95% CI 1.43–7.77). Symptom severity differed among groups, with higher cough and sputum scores in the NI-NV group and greater dyspnea severity in the NV-I group. Neither prior SARS-CoV-2 infection nor COVID-19 vaccination was associated with increased airway hypersensitivity after adjustment for confounders. Despite similar objective airway responsiveness, symptom severity varied across groups, suggesting a dissociation between subjective respiratory symptoms and measurable bronchial hyperresponsiveness.Keywords
This publication has 31 references indexed in Scilit:
- SARS-CoV-2 pathophysiology and post-vaccination severity: a systematic reviewImmunologic Research, 2024
- Impact of Ongoing Treatment With Inhaled Corticosteroids During Specific Inhalation Challenges for Diagnosing Occupational AsthmaThe Journal of Allergy and Clinical Immunology: In Practice, 2024
- The association between COVID-19 vaccine/infection and new-onset asthma in children - based on the global TriNetX databaseInfection, 2024
- Epidemiology of acute kidney injury in children: a report from the 26th Acute Disease Quality Initiative (ADQI) consensus conferencePediatric Nephrology, 2023
- Global burden of chronic respiratory diseases and risk factors, 1990–2019: an update from the Global Burden of Disease Study 2019eClinicalMedicine, 2023
- Efficacy of biologic therapy on airway hyperresponsiveness in asthmaAnnals of Allergy, Asthma & Immunology, 2023
- Pulmonary Procedures During the COVID-19 Pandemic: A Work Group Report of the AAAAI Asthma Diagnosis and Treatment (ADT) Interest SectionThe Journal of Allergy and Clinical Immunology: In Practice, 2022
- An Acute Exacerbation of Idiopathic Pulmonary Fibrosis After BNT162b2 mRNA COVID-19 VaccinationChest, 2022
- Eosinophilic Pneumonia Associated to SARS-CoV-2 VaccineArchivos de Bronconeumología, 2021
- Allergic Endotypes and Phenotypes of AsthmaThe Journal of Allergy and Clinical Immunology: In Practice, 2020